This federal contract award, SPE2DP16D0008|0051, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The $76,496.94 firm-fixed-price delivery order is for the supply of oseltamivir phosphate, an antiviral medication, with a period of performance through September 11, 2018.
Genentech holds several major contract vehicles with federal agencies like the Department of Veterans Affairs and the Department of Defense to efficiently provide pharmaceuticals and biologics. This delivery order is likely part of the company's $27.9 million indefinite delivery contract with DLA to fulfill orders for critical medical supplies and pharmaceuticals supporting the Department of Defense's global health logistics network. The contract does not have a set-aside designation. Genentech has a strong track record of supplying a wide range of pharmaceutical products and services to meet federal agencies' needs for stockpiling, treatment, and emergency preparedness.